Interview: Natco's financing plan to strengthen US generics thrust
This article was originally published in Scrip
Executive Summary
Natco Pharma expects to raise Rs1 billion ($22 million) to part finance plans to develop its US generics business. The Indian company, which has a rich pipeline of Paragraph IV filings in the US, is also upbeat about the prospects of its early stage NCEs in the oncology segment.